Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1

Immune checkpoint inhibitors utilize the immune system to kill cancer cells and are now widely applied across numerous malignancies. Pembrolizumab has two breast-specific indications in triple-negative disease. Currently, programmed death ligand-1 (PD-L1) expression on tumor and surrounding immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Nan, Higashiyama, Nicole, Hoyos, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698415/
https://www.ncbi.nlm.nih.gov/pubmed/34944679
http://dx.doi.org/10.3390/biomedicines9121863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698415/
https://www.ncbi.nlm.nih.gov/pubmed/34944679
http://dx.doi.org/10.3390/biomedicines9121863

Ejemplares similares